JP2021526123A - オートタキシン阻害剤とその使用 - Google Patents
オートタキシン阻害剤とその使用 Download PDFInfo
- Publication number
- JP2021526123A JP2021526123A JP2020540731A JP2020540731A JP2021526123A JP 2021526123 A JP2021526123 A JP 2021526123A JP 2020540731 A JP2020540731 A JP 2020540731A JP 2020540731 A JP2020540731 A JP 2020540731A JP 2021526123 A JP2021526123 A JP 2021526123A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*(N=C1**)=*)=C1IC Chemical compound CC(*(N=C1**)=*)=C1IC 0.000 description 3
- RSGKDTWQQCLALX-UHFFFAOYSA-N CCOC(CCN(C=C)N=C)=O Chemical compound CCOC(CCN(C=C)N=C)=O RSGKDTWQQCLALX-UHFFFAOYSA-N 0.000 description 2
- SRUMNHVGGOLUBW-UHFFFAOYSA-N CCc1n[n](ccc(Br)c2)c2c1C(OCC)=O Chemical compound CCc1n[n](ccc(Br)c2)c2c1C(OCC)=O SRUMNHVGGOLUBW-UHFFFAOYSA-N 0.000 description 2
- YLACRFYIUQZNIV-UHFFFAOYSA-N NOc(c([N+]([O-])=O)c1)ccc1[N+]([O-])=O Chemical compound NOc(c([N+]([O-])=O)c1)ccc1[N+]([O-])=O YLACRFYIUQZNIV-UHFFFAOYSA-N 0.000 description 2
- AVPKHOTUOHDTLW-UHFFFAOYSA-N OC(C1CCOCC1)=O Chemical compound OC(C1CCOCC1)=O AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 2
- BOTREHHXSQGWTR-BYPYZUCNSA-N OC([C@@H]1COCC1)=O Chemical compound OC([C@@H]1COCC1)=O BOTREHHXSQGWTR-BYPYZUCNSA-N 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-M [O-]c(c([N+]([O-])=O)c1)ccc1[N+]([O-])=O Chemical compound [O-]c(c([N+]([O-])=O)c1)ccc1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-M 0.000 description 2
- JQIVMANCSCPGCB-UHFFFAOYSA-O CC(C)(C)OC(Nc(c(F)c1)cc[n+]1N)=O Chemical compound CC(C)(C)OC(Nc(c(F)c1)cc[n+]1N)=O JQIVMANCSCPGCB-UHFFFAOYSA-O 0.000 description 1
- XYSXAPOKAACROT-UHFFFAOYSA-O CC(C)(C)OC(Nc(cc1)c(C)c[n+]1N)=O Chemical compound CC(C)(C)OC(Nc(cc1)c(C)c[n+]1N)=O XYSXAPOKAACROT-UHFFFAOYSA-O 0.000 description 1
- RZPXITSRAQPKRU-UHFFFAOYSA-N CC(C)(C)OC(Nc1ccncc1C)=O Chemical compound CC(C)(C)OC(Nc1ccncc1C)=O RZPXITSRAQPKRU-UHFFFAOYSA-N 0.000 description 1
- WIZGKLCQBIOGNX-UHFFFAOYSA-N CC(C)(C)OC(Nc1ccncc1F)=O Chemical compound CC(C)(C)OC(Nc1ccncc1F)=O WIZGKLCQBIOGNX-UHFFFAOYSA-N 0.000 description 1
- HXRVBCVIMWGCHJ-UHFFFAOYSA-N CC(NC)N1CC2(CNC2)C1 Chemical compound CC(NC)N1CC2(CNC2)C1 HXRVBCVIMWGCHJ-UHFFFAOYSA-N 0.000 description 1
- DXVZDXHKYLRKIO-KQQUZDAGSA-N CCC(C(C1/C=C/N)C(OCC)=O)=NN1/C=C/F Chemical compound CCC(C(C1/C=C/N)C(OCC)=O)=NN1/C=C/F DXVZDXHKYLRKIO-KQQUZDAGSA-N 0.000 description 1
- YTOVSUIESNDTJO-UHFFFAOYSA-N CCC1=CCN(C=C(C(NC(OC(C)(C)C)=O)=C2)F)C2=C1C(OCC)=O Chemical compound CCC1=CCN(C=C(C(NC(OC(C)(C)C)=O)=C2)F)C2=C1C(OCC)=O YTOVSUIESNDTJO-UHFFFAOYSA-N 0.000 description 1
- QFXBNQPQLGOFBL-UHFFFAOYSA-N CCN(C=C)N=C Chemical compound CCN(C=C)N=C QFXBNQPQLGOFBL-UHFFFAOYSA-N 0.000 description 1
- KSMPPWBBWHPZQE-UHFFFAOYSA-N CCNC(N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1)=C Chemical compound CCNC(N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1)=C KSMPPWBBWHPZQE-UHFFFAOYSA-N 0.000 description 1
- AWIFQANGOVMGCK-IBGZPJMESA-N CC[n]1nc2ncc(N(CC3)CCN3C([C@@H]3COCC3)=O)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 Chemical compound CC[n]1nc2ncc(N(CC3)CCN3C([C@@H]3COCC3)=O)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 AWIFQANGOVMGCK-IBGZPJMESA-N 0.000 description 1
- YNOVDDRMDFMQMT-UHFFFAOYSA-N CCc1n[n](cc(C)c(NC(OC(C)(C)C)=O)c2)c2c1C(OCC)=O Chemical compound CCc1n[n](cc(C)c(NC(OC(C)(C)C)=O)c2)c2c1C(OCC)=O YNOVDDRMDFMQMT-UHFFFAOYSA-N 0.000 description 1
- CPIYJGOUWGLLOU-UHFFFAOYSA-N CCc1n[n](cc(c(Br)c2)F)c2c1C(OCC)=O Chemical compound CCc1n[n](cc(c(Br)c2)F)c2c1C(OCC)=O CPIYJGOUWGLLOU-UHFFFAOYSA-N 0.000 description 1
- UHLVHQMGNIWEII-UHFFFAOYSA-N CCc1n[n](cc(c(NC(OC(C)(C)C)=O)c2)F)c2c1C(OCC)=O Chemical compound CCc1n[n](cc(c(NC(OC(C)(C)C)=O)c2)F)c2c1C(OCC)=O UHLVHQMGNIWEII-UHFFFAOYSA-N 0.000 description 1
- HDZVVZSEQYSANF-UHFFFAOYSA-N CCc1n[n](ccc(Br)c2)c2c1C(O)=O Chemical compound CCc1n[n](ccc(Br)c2)c2c1C(O)=O HDZVVZSEQYSANF-UHFFFAOYSA-N 0.000 description 1
- LYUAJXLQOADBGH-UHFFFAOYSA-N CCc1n[n]2c(C)cc(N(C3)CC3(CC3)CN3C(C3CCOCC3)=O)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 Chemical compound CCc1n[n]2c(C)cc(N(C3)CC3(CC3)CN3C(C3CCOCC3)=O)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 LYUAJXLQOADBGH-UHFFFAOYSA-N 0.000 description 1
- SSRNYPOEOZSSIJ-UHFFFAOYSA-N CCc1n[n]2c(C)cc(N(C3)CC3(CC3)CN3C(C3CN(C)C3)=O)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 Chemical compound CCc1n[n]2c(C)cc(N(C3)CC3(CC3)CN3C(C3CN(C)C3)=O)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 SSRNYPOEOZSSIJ-UHFFFAOYSA-N 0.000 description 1
- HOAKTBYRTWQMGQ-UHFFFAOYSA-N CCc1n[n]2c(C)cc(N(C3)CC33CNCC3)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 Chemical compound CCc1n[n]2c(C)cc(N(C3)CC33CNCC3)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 HOAKTBYRTWQMGQ-UHFFFAOYSA-N 0.000 description 1
- RKHAFCUYGYWBCJ-QFIPXVFZSA-N CCc1n[n]2c(C)cc(N3CC(C4)(CN4C([C@@H]4COCC4)=O)CC3)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 Chemical compound CCc1n[n]2c(C)cc(N3CC(C4)(CN4C([C@@H]4COCC4)=O)CC3)cc2c1N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 RKHAFCUYGYWBCJ-QFIPXVFZSA-N 0.000 description 1
- UEEONKMEDZJUDW-UHFFFAOYSA-N Cc([n]1nc2C3CC3)cc(N(CC3)CCN3C(C3(CCOCC3)OC)=O)cc1c2N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 Chemical compound Cc([n]1nc2C3CC3)cc(N(CC3)CCN3C(C3(CCOCC3)OC)=O)cc1c2N(C)c1nc(-c(cc2)ccc2F)c(C#N)[s]1 UEEONKMEDZJUDW-UHFFFAOYSA-N 0.000 description 1
- SSNJLHFUWJOKBC-UHFFFAOYSA-N Cc1nc2n[nH]c(N(C)c3nc(-c(cc4)ccc4F)c(C#N)[s]3)c2cc1N1CCNCC1 Chemical compound Cc1nc2n[nH]c(N(C)c3nc(-c(cc4)ccc4F)c(C#N)[s]3)c2cc1N1CCNCC1 SSNJLHFUWJOKBC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677459P | 2018-05-29 | 2018-05-29 | |
| US62/677,459 | 2018-05-29 | ||
| US201862731003P | 2018-09-13 | 2018-09-13 | |
| US62/731,003 | 2018-09-13 | ||
| PCT/CN2019/089025 WO2019228403A1 (en) | 2018-05-29 | 2019-05-29 | Autotaxin inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021526123A true JP2021526123A (ja) | 2021-09-30 |
| JP2021526123A5 JP2021526123A5 (enExample) | 2022-05-27 |
Family
ID=68697812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540731A Pending JP2021526123A (ja) | 2018-05-29 | 2019-05-29 | オートタキシン阻害剤とその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10711000B2 (enExample) |
| EP (1) | EP3728257A4 (enExample) |
| JP (1) | JP2021526123A (enExample) |
| CN (1) | CN111801328B (enExample) |
| CA (1) | CA3089527A1 (enExample) |
| WO (1) | WO2019228403A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021513551A (ja) * | 2018-02-14 | 2021-05-27 | スーチョウ、シノベント、ファーマスーティカルズ、カンパニー、リミテッドＳｕｚｈｏｕ Ｓｉｎｏｖｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | 複素環式化合物、その応用及びそれを含有する医薬組成物 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019228403A1 (en) | 2018-05-29 | 2019-12-05 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
| CN111393459B (zh) * | 2020-04-16 | 2022-07-22 | 南京安纳康生物科技有限公司 | Shp2抑制剂及其用途 |
| US20230295159A1 (en) * | 2020-07-09 | 2023-09-21 | Suzhou Ark Biopharmaceutical Co., Ltd. | Atx inhibitor, and preparation method therefor and use thereof |
| CN113912600A (zh) * | 2020-07-09 | 2022-01-11 | 苏州爱科百发生物医药技术有限公司 | 一种atx抑制剂及其制备方法和应用 |
| JP2023536159A (ja) * | 2020-07-31 | 2023-08-23 | ジェネンテック， インコーポレイテッド | 炎症性呼吸器疾患の増悪を治療するための方法 |
| CN114315825A (zh) * | 2020-09-30 | 2022-04-12 | 江西济民可信集团有限公司 | 吡啶并咪唑衍生物及其制备方法和应用 |
| WO2022074459A2 (en) * | 2020-10-06 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Autotaxin inhibitor compounds |
| EP4242208A4 (en) * | 2020-11-04 | 2025-01-15 | Xizang Haisco Pharmaceutical Co., Ltd. | DEUTERATED DERIVATIVE USED AS ATX INHIBITOR, AND ITS APPLICATION |
| CN112675308B (zh) * | 2020-12-09 | 2023-05-05 | 中国人民解放军军事科学院军事医学研究院 | 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用 |
| JP2024502337A (ja) | 2021-01-05 | 2024-01-18 | ザイダス ライフサイエンシズ リミティド | オートタキシンの新規阻害剤 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| TW202342138A (zh) * | 2022-03-31 | 2023-11-01 | 大陸商蘇州愛科百發生物醫藥技術有限公司 | Ａｔｘ抑制劑或其鹽的結晶形式及其制備方法與應用 |
| EP4514348A4 (en) * | 2022-04-29 | 2025-12-31 | Noetix Pharma Llc | PREVENTION AND TREATMENT OF POSTOPERATIVE COGNITIVE DYSFUNCTIONS (POCD) |
| EP4543870A1 (en) * | 2022-06-24 | 2025-04-30 | F. Hoffmann-La Roche AG | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139882A1 (en) * | 2013-03-14 | 2014-09-18 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2014202458A1 (en) * | 2013-06-19 | 2014-12-24 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2019158107A1 (zh) * | 2018-02-14 | 2019-08-22 | 苏州信诺维医药科技有限公司 | 一种杂环化合物、其应用及含其的药物组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201908293A (zh) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| CA3108809C (en) | 2018-05-24 | 2023-08-29 | Guangzhou Henovcom Bioscience Co., Ltd. | Heteroaromatic compounds, pharmaceutical compositions and uses thereof |
| WO2019228403A1 (en) | 2018-05-29 | 2019-12-05 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
-
2019
- 2019-05-29 WO PCT/CN2019/089025 patent/WO2019228403A1/en not_active Ceased
- 2019-05-29 CN CN201980015925.4A patent/CN111801328B/zh active Active
- 2019-05-29 CA CA3089527A patent/CA3089527A1/en active Pending
- 2019-05-29 EP EP19810155.2A patent/EP3728257A4/en not_active Withdrawn
- 2019-05-29 JP JP2020540731A patent/JP2021526123A/ja active Pending
- 2019-07-11 US US16/509,300 patent/US10711000B2/en not_active Expired - Fee Related
-
2020
- 2020-05-15 US US16/875,675 patent/US11040972B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139882A1 (en) * | 2013-03-14 | 2014-09-18 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2014202458A1 (en) * | 2013-06-19 | 2014-12-24 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2019158107A1 (zh) * | 2018-02-14 | 2019-08-22 | 苏州信诺维医药科技有限公司 | 一种杂环化合物、其应用及含其的药物组合物 |
Non-Patent Citations (3)
| Title |
|---|
| JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN6023025388, 1 May 2017 (2017-05-01), pages 3580 - 3590, ISSN: 0005086903 * |
| JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN6023025389, 18 August 2017 (2017-08-18), pages 7371 - 7392, ISSN: 0005086902 * |
| 野崎 正勝 他, 創薬化学, vol. 第1版, JPN7023001664, 1995, JP, pages 98 - 99, ISSN: 0005086904 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021513551A (ja) * | 2018-02-14 | 2021-05-27 | スーチョウ、シノベント、ファーマスーティカルズ、カンパニー、リミテッドＳｕｚｈｏｕ Ｓｉｎｏｖｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | 複素環式化合物、その応用及びそれを含有する医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3728257A1 (en) | 2020-10-28 |
| US10711000B2 (en) | 2020-07-14 |
| US20190367515A1 (en) | 2019-12-05 |
| EP3728257A4 (en) | 2021-06-23 |
| CN111801328B (zh) | 2023-06-02 |
| CN111801328A (zh) | 2020-10-20 |
| WO2019228403A1 (en) | 2019-12-05 |
| CA3089527A1 (en) | 2019-12-05 |
| US11040972B2 (en) | 2021-06-22 |
| US20200354357A1 (en) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526123A (ja) | オートタキシン阻害剤とその使用 | |
| AU2020343671C1 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| EP3692040B1 (en) | Chemical compounds | |
| AU2018332501B2 (en) | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | |
| JP6204985B2 (ja) | ＲＯＲγＴ阻害剤としての３−アミノシクロアルキル化合物およびその使用 | |
| JP6402179B2 (ja) | 新規な、ＮＩＫ阻害剤としての１−（４−ピリミジニル）−１Ｈ−ピロロ［３，２−ｃ］ピリジン誘導体 | |
| JP2022505987A (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| KR20250172881A (ko) | 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도 | |
| US20240246932A1 (en) | Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| EP3766882B1 (en) | Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof | |
| MX2015001941A (es) | Compuestos de ácido benzoico 4-heteroarilo-sustituido como inhibidores de rorgammat y sus usos. | |
| WO2007055418A1 (ja) | アザ置換スピロ誘導体 | |
| EA007063B1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β; | |
| CA2957898C (en) | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists | |
| EA023574B1 (ru) | ПРОИЗВОДНЫЕ 6-ЦИКЛОБУТИЛ-1,5-ДИГИДРОПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE9A | |
| US20200071326A1 (en) | Tam kinase inhibitors | |
| JP2022525948A (ja) | 高血糖症の治療に有用なヘテロアリール（ヘテロシクリル）メタノール化合物 | |
| WO2016088813A1 (ja) | 新規ジアザビシクロ［２．２．２］オクタン誘導体 | |
| JP2022525795A (ja) | 高血糖症の治療に有用なヘテロシクロリル（フェニル）メタノール化合物 | |
| JP2025094217A (ja) | 併用医薬による糖尿病の治療又は予防方法 | |
| JP2024529508A (ja) | ピロロ［２，３－ｂ］ピリジンＰＧＤＨ阻害剤、および製造方法ならびに使用方法 | |
| US20250235510A1 (en) | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist peptides | |
| US20260055057A1 (en) | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof | |
| WO2026078674A1 (en) | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof | |
| RU2775505C2 (ru) | Изохинолин-3-иловые карбоксамиды и их получение и применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201029 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210629 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20220425 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20220427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220519 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220519 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230620 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230912 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231212 |